Amplifi Vascular Announces Successful First-in-Human Study Results, Closes $6.8M Series A, and Receives FDA IDE Approval
Company announces positive first-in-human study results, the close of a $6.9 million Series A financing, and FDA approval of its Investigational Device Exemption.
ST. LOUIS, Oct. 9, 2025 /PRNewswire/ -- Amplifi Vascular, developer of the first-of-its-kind Vein Dilation System designed to increase eligibility, improve creation and early maturation of arteriovenous fistulas (AVFs) for hemodialysis, today announced three major milestones: positive first-in-human (FIH) study results, the close of a $6.9 million Series A financing, and U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE).
The Amplifi FIH Study enrolled nineteen (19) patients to pre-dilate veins prior to surgical AVF creation. The study met its primary objectives, with rapid post-procedure vein enlargement supporting successful fistula creation, physiological maturation (≥5mm in diameter and ≥500ml/min flow), and early functional use. No significant device-related adverse events were reported. Results support the system's potential to address the root cause of extended time to maturation and historical high degree of failure leading to an increase in rates of forearm AVF success and to potentially reduce the dependence on dialysis catheters and grafts.
"Our first-in-human study not only met its primary objectives but also demonstrated rapid post-procedure vein enlargement, facilitating successful fistula creation, physiological maturation, and early functional use," stated Sean Morris, President and Chief Executive, Amplifi Vascular. "Furthermore, the FDA IDE approval empowers us to commence a U.S. clinical investigation, directly addressing the underlying causes of extended maturation times and elevated failure rates in AVF creation."
FDA IDE approval enables Amplifi to initiate AMPLIFI-1, a U.S. clinical investigation evaluating safety, performance, and time to functional maturation compared with standard care. Surendra Shenoy, MD, Washington University, St. Louis School of Medicine said, "Early outcomes suggest that proactive vein dilation prior to AVF surgery can significantly improve the likelihood of achieving a usable fistula sooner—an outcome that matters greatly to our dialysis patients."
About Amplifi Vascular Amplifi Vascular is a medical device company focused on improving hemodialysis access by enabling reliable, early maturing forearm AVFs. The Amplifi Vein Dilation System delivers a controlled, temporary therapy to enlarge target veins prior to surgical fistula creation, aiming to increase success rates, reduce catheter days and re-interventions, and lower overall costs of care.
View original content to download multimedia:https://www.prnewswire.com/news-releases/amplifi-vascular-announces-successful-first-in-human-study-results-closes-6-8m-series-a-and-receives-fda-ide-approval-302580270.html
SOURCE Amplifi Vascular, Inc